**SUPPLEMENTARY MATERIALS**

**Ethical consideration**

Human subject study was approved by the Scientific and IRB ethics committee of the School of Medicine and Public Health (SMPH), University of Wisconsin (UW)-Madison and studies were performed following the Declaration of Helsinki protocols. All animal experiments were performed in compliance with the School of Medicine and Public Health (SMPH) Institutional Animal Care and Use Committee (IACUC) guidelines and protocols were approved by the Animal Care and Use Committee at the University of Wisconsin-Madison (Madison, WI).

**Mice and IMQ-induce murine psoriasis-like skin model:** Six–to-eight-week-old male Balb/c mice from Harlan laboratories (Madison, WI) were used. After arrival, mice were acclimatized for 1 week before commencing the experiments, and were maintained under standard pathogen-free conditions: temperature of 24 ± 2°C, relative humidity of 50 ± 10% and 12 h room light/12 h dark cycle, and fed Purina Chow diet and water ad libitum. The dorsal surface of Balb/c mice were shaved with electrical clippers and residual hair cleared with Nair, and mice were allowed to rest for 48 hours before all experiments. Mice received daily topical dose of 62.5 mg of commercially available IMQ cream (5%) (Aldara, 3M Pharmaceuticals), on the shaved back for 5 days, and received the same booster dose for 9 consecutive days to achieve optimal chronic inflammation. For controls, mice received Vaseline, since the IMQ vehicle has been shown to induce inflammatory responses (S1). All imQ-treated (n = 6) and pair-matched control (n = 6) mouse skin were freshly harvested as earlier described (11), for histological and biochemical analyses.

**Patients and healthy human tissue collection.** Thin cuts; 6-µm cryo-sections or 5-µm paraffin sections were obtained from all fresh healthy skin (n = 6) including different clinical grades mild, moderate and severe plaque-type, and fresh healthy skin (n = 10) taken after written informed consent. For controls, mice received Vaseline, since the IMQ vehicle has been shown to induce inflammatory responses (S1). All IMQ-treated (n = 6) and pair-matched control (n = 6) mouse skin were freshly harvested as earlier described (11), for histological and biochemical analyses.

**Histology, immunohistochemistry and immunofluorescence.** Paraffin embedded and frozen cryo-sections from inflamed psoriatic, IMQ-induced mouse skin lesions and their respective matched control skin tissues were processed for histology and immunostaining as previously described (S2, S3). Briefly, paraffin-embedded samples were de-paraffinized, heated and pretreated at 95°C for 50 min in 10 mmol L−1 sodium citrate (pH 6.0) in a Steamer set at 120°C (IHCWORLD, LLC, Life Science). Frozen sections were fixed in acetone and permeabilized with TBS-T [50 mmol L−1 Tris–HCl (pH 7.5), 150 mmol L−1 NaCl, 0.3% Triton X-100]. For immunofluorescence (IF), all specimens were blocked with 10% normal goat serum (NGS)/2% bovine serum albumin (BSA) dissolved in TBS-T for 30 min whereas, sections stained by immunohistochemistry (IHC) were blocked in 5% NGS/horse serum/2% BSA in TBS-T for 1 hr at room temperature (RT) and incubated overnight at 4°C with the following primary or isotype controls antibodies. The antibodies used were: rabbit anti-phospho-Akt (Ser473(1:250, #4060); Thr308(1:200, #13083)), rabbit anti-phospho-mTOR (Ser2448(D9C2) (1:200, #55361)), rabbit anti-phospho-S6(Ser235/236) (1:400; #2211), rabbit anti-phospho-S6(Ser240/244) (1:400; #2215), rabbit anti-Pi3 Kinase (p110α (C73F8) (1:200; # 4249), rabbit anti-P-p44/42(Thr202/ Tyr204) (1:200; # 4370) and rabbit anti-phospho-Stat3 (Tyr705) (1:200; #9145) all from (Cell Signaling, Danvers, MA); rabbit anti-phospho-mTOR (Ser2481(1:200, # ab45996) from abcam; mouse antiphospho-S6(Ser240) (1:100; DAKO #M7300); rabbit anti-PCNA (1:200; DAKO #A0067); mouse anti-CD45 (1:100; DAKO #M0701), rabbit anti-PPARβ/δ (1:200; #NBPI-39684, Novus Biologicals), rat anti-mCD4 (1:200; # MAB114; R&D System); rabbit anti-fABP5 (1:200; #12345-IAP ProteinTech Group) and anti-hFABP5 (1:200; # AF3077, R&D Systems). After washing, IF samples were incubated for 1 h with Alexa Fluor 488 or Alexa Fluor 594 HRP-conjugated secondary antibodies (1:600; Invitrogen), and following several washes were mounted with Prolong® Gold Anti-fade reagent containing 4′,6-diamidino-2-phenylindole (DAPI; Invitrogen). IHC stained samples were processed as described earlier (S2, S3). Images were generated using the Nuance EX/FX and Vectra™ (PerkinElmer, Boston, MA) multiplexing image technology platform and analyzed by the InForm software. Control immunostaining utilizing mouse melanoma tumor treated with dual mTOR inhibitor (fisetin) or placebo confirmed the phospho-S6 antibodies are highly specific for Akt/mTOR-regulated phosphorylation sites. Control sections were prepared following incubation with the appropriate isotype control mAb or following addition of biotinylated mAb conjugate or secondary conjugated antibody alone.

**Preparation of tissue lysates and Western Blot analysis.** Mouse skin biopsied tissues were lysed, homogenized, ultra-sonicated in ice-cold Cell Lysis Buffer (affymetrix, # EPX-99999-000) freshly supplemented with 1mM PMSF and protease inhibitor cocktail Set III (Calbiochem). The lysates were quantified and normalized as earlier described (S2, 8). Thirty microgram (30 µg) of each protein sample was subjected to SDS 12% polyacrylamide gel electrophoresis (PAGE) and blotted onto nitrocellulose membranes. After 45 min blocking in 5% nonfat dry milk in TBS-T, membranes were probed with the indicated PathScan® Multiplex Western Cocktail I (1:200; #5301) antibody (Cell Signaling, Danvers, MA) overnight at 4°C. Samples were incubated for 1 hr with horse-radish peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies (Cell Signaling Technology or Pierce/Thermo Fischer Scientific), developed with ECL (GE Healthcare) and Super Signal West Femto chemiluminescent substrate (Pierce/Thermo Fischer Scientific) and visualized using an automatic imager (Bio Rad) as described (8).

**SUPPLEMENTARY REFERENCES**

